HKUMed Unveils AI Blood Test Predicting 6 Heart Diseases Up to 15 Years Early
Updated
Updated · SciTechDaily · May 22
HKUMed Unveils AI Blood Test Predicting 6 Heart Diseases Up to 15 Years Early
1 articles · Updated · SciTechDaily · May 22
CardiOmicScore, developed by HKUMed researchers, uses a single blood test to estimate future risk of six major cardiovascular diseases and flag danger signs up to 15 years before symptoms appear.
The model combines deep learning with multiomics data—genomics, proteomics and metabolomics—to read 2,920 circulating proteins and 168 metabolites as real-time signals of immune, metabolic and vascular health.
HKUMed said the tool outperformed conventional polygenic risk scores and gained further accuracy when paired with clinical factors such as age and sex.
The advance targets a major prevention gap: cardiovascular disease killed about 19.8 million people in 2022, while standard risk checks can miss early biological changes and genetic scores cannot track lifestyle-driven shifts over time.
Published in Nature Communications, the study points toward broader precision-medicine screening in which a small blood sample could generate a multi-disease cardiovascular risk profile.
This AI blood test predicts heart disease years away, so why do insurers call it unproven?
AI can now predict your future heart attack risk. But is this knowledge a blessing or a curse?
Trained on UK data, can this new AI heart test work fairly for the rest of the world?
15-Year Early Warning for Heart Disease: The Promise and Challenges of CardiOmicScore’s AI Multiomics Approach
Overview
In March 2026, researchers at HKUMed announced CardiOmicScore, a groundbreaking technology that marks a major advance in heart disease prevention. Unlike traditional methods that focus on treating existing conditions, CardiOmicScore shifts healthcare toward proactive prevention by predicting the onset of six major cardiovascular diseases up to 15 years before symptoms appear. This system uses sophisticated data analysis to identify and prevent diseases before they fully develop, offering an unprecedented window for early intervention. The goal is to empower both patients and clinicians to act early, fundamentally changing how heart disease is managed.